Several additional therapeutics with various mechanisms of action, including carbetocin, setmelanotide, diazoxide choline controlled release, unacylated ghrelin, tesofensine/metoprolol, and several glucagon-like peptide 1 receptor agonists, are currently in clinical trials for the treatment of hyperphagia and obesity (42, 220–223). This evidence concerns the gene GHRL and obesity disorder.